Editorial Expression of Concern: Herpes simplex virus thymidine kinase/ganciclovir–induced cell death is enhanced by co-expression of caspase-3 in ovarian carcinoma cells
Cancer Gene Therapy, Published online: 02 May 2024; doi:10.1038/s41417-024-00777-5Editorial Expression of Concern: Herpes simplex virus thymidine kinase/ganciclovir–induced cell death is enhanced by co-expression of caspase-3 in ovarian carcinoma cells (Source: Cancer Gene Therapy)
Source: Cancer Gene Therapy - May 2, 2024 Category: Cancer & Oncology Authors: I. A. McNeish T. Tenev S. Bell M. Marani G. Vassaux N. Lemoine Source Type: research
Therapeutic vaccines for herpesviruses
Herpesviruses establish latent infections, and most reactivate frequently, resulting in symptoms and virus shedding in healthy individuals. In immunocompromised patients, reactivating virus can cause severe disease. Persistent EBV has been associated with several malignancies in both immunocompromised and nonimmunocompromised persons. Reactivation and shedding occur with most herpesviruses, despite potent virus-specific antibodies and T cell immunity as measured in the blood. The licensure of therapeutic vaccines to reduce zoster indicates that effective therapeutic vaccines for other herpesviruses should be feasible. Howe...
Source: Journal of Clinical Investigation - May 1, 2024 Category: Biomedical Science Authors: Jeffrey I. Cohen Source Type: research
VP5 protein of oncolytic herpes simplex virus type 2 induces apoptosis in A549 cells through TP53I3 protein
Virology. 2024 Apr 25;595:110093. doi: 10.1016/j.virol.2024.110093. Online ahead of print.ABSTRACTOncolytic virotherapy stands out as a burgeoning and promising therapeutic paradigm, harnessing the intrinsic cytotoxicity of oncolytic viruses for selective replication and dissemination within tumors. The primary mode of action revolves around the direct eradication of tumor cells. In our previous investigations, we formulated an oncolytic herpes simplex virus type 2 (OH2) and substantiated its anti-tumor efficacy both in vivo and in vitro. Subsequently, we embarked on a phase I/II clinical trial in China (NMPA, 2018L02743) ...
Source: Herpes - May 1, 2024 Category: Infectious Diseases Authors: Yang Wang Hui Zhang Qin Zhou Wen Xia Xiaotong Zhao Le Li Xinya Wang Jingru Yang Xinxin Ren Jian Wu Han Hu Binlei Liu Source Type: research
Prevalence of Diagnosed Genital Herpes and Antiviral Treatment in the United States
CONCLUSIONS: The burden of genital herpes and recurrent genital herpes in the US is substantial, with the highest rates observed in young adults, women, and immunocompromised individuals. About two-thirds receive antiviral treatment each year.PMID:38691406 | DOI:10.1097/OLQ.0000000000001990 (Source: Herpes)
Source: Herpes - May 1, 2024 Category: Infectious Diseases Authors: Purva Jain Alan Embry Brent Arakaki Irisdaly Estevez Zachary A Marcum Emma Viscidi Source Type: research
Therapeutic vaccines for herpesviruses
J Clin Invest. 2024 May 1;134(9):e179483. doi: 10.1172/JCI179483.ABSTRACTHerpesviruses establish latent infections, and most reactivate frequently, resulting in symptoms and virus shedding in healthy individuals. In immunocompromised patients, reactivating virus can cause severe disease. Persistent EBV has been associated with several malignancies in both immunocompromised and nonimmunocompromised persons. Reactivation and shedding occur with most herpesviruses, despite potent virus-specific antibodies and T cell immunity as measured in the blood. The licensure of therapeutic vaccines to reduce zoster indicates that effect...
Source: Herpes - May 1, 2024 Category: Infectious Diseases Authors: Jeffrey I Cohen Source Type: research
Efficacy and Safety of Amenamevir, a Helicase-Primase Inhibitor for the Treatment of Acyclovir-Resistant Herpes Simplex Virus 1 Keratitis
CONCLUSIONS: Although there was no control group, AMNV may be a valuable option to reduce ACVR HSK recurrences.PMID:38692653 | DOI:10.1097/ICO.0000000000003553 (Source: Herpes)
Source: Herpes - May 1, 2024 Category: Infectious Diseases Authors: Rafael Boucher David Boutolleau Sonia Burrel Oscar Haigh Jos é Fernandez Christelle Vauloup-Fellous Emmanuel Barreau Antoine Rousseau Marc Labetoulle Source Type: research
VP5 protein of oncolytic herpes simplex virus type 2 induces apoptosis in A549 cells through TP53I3 protein
Virology. 2024 Apr 25;595:110093. doi: 10.1016/j.virol.2024.110093. Online ahead of print.ABSTRACTOncolytic virotherapy stands out as a burgeoning and promising therapeutic paradigm, harnessing the intrinsic cytotoxicity of oncolytic viruses for selective replication and dissemination within tumors. The primary mode of action revolves around the direct eradication of tumor cells. In our previous investigations, we formulated an oncolytic herpes simplex virus type 2 (OH2) and substantiated its anti-tumor efficacy both in vivo and in vitro. Subsequently, we embarked on a phase I/II clinical trial in China (NMPA, 2018L02743) ...
Source: Virology - May 1, 2024 Category: Virology Authors: Yang Wang Hui Zhang Qin Zhou Wen Xia Xiaotong Zhao Le Li Xinya Wang Jingru Yang Xinxin Ren Jian Wu Han Hu Binlei Liu Source Type: research
Performance characteristics of highly automated HSV-1 and HSV-2 IgG testing
This study is the first large-scale comparison of performance metrics for the Bio-Rad and Roche assays in over 10 years. Our study confirms that there remains room for improvement in HSV serological diagnostic testing-especially in regard to low sensitivities for HSV-1 IgG detection-and highlights that some previously less-studied assays may have better performance metrics than previously considered typical of commercially available HSV-2 IgG assays.PMID:38687020 | DOI:10.1128/jcm.00263-24 (Source: Herpes)
Source: Herpes - April 30, 2024 Category: Infectious Diseases Authors: Katharine H D Crawford Stacy Selke Gregory Pepper Erin Goecker Aniela Sobel Anna Wald Christine Johnston Alexander L Greninger Source Type: research
Clinical characteristics and outcomes of acute liver failure in neonates: a retrospective cohort in China
Conclusion: Hypoxic/ischemic injury and infection are the predominant etiologies of NALF in China. The overall prognosis of NALF is poor, but its short-term prognosis is determined by the etiology. What is Known: • Neonatal acute liver failure (NALF) is a rare disorder with limited cohort studies, especially in China. • Gestational alloimmune liver disease, viral infections (especially herpes simplex virus), metabolic diseases and ischemic insults are common etiologies of NALF, which are significantly different from other populations. • There are no reliable biochemical markers to predict the outcome of NALF. What is...
Source: Herpes - April 30, 2024 Category: Infectious Diseases Authors: Suhua Xu Peng Zhang Mengmeng Ge Yuanyuan Shan Guoqiang Cheng Source Type: research
Performance characteristics of highly automated HSV-1 and HSV-2 IgG testing
This study is the first large-scale comparison of performance metrics for the Bio-Rad and Roche assays in over 10 years. Our study confirms that there remains room for improvement in HSV serological diagnostic testing-especially in regard to low sensitivities for HSV-1 IgG detection-and highlights that some previously less-studied assays may have better performance metrics than previously considered typical of commercially available HSV-2 IgG assays.PMID:38687020 | DOI:10.1128/jcm.00263-24 (Source: Herpes)
Source: Herpes - April 30, 2024 Category: Infectious Diseases Authors: Katharine H D Crawford Stacy Selke Gregory Pepper Erin Goecker Aniela Sobel Anna Wald Christine Johnston Alexander L Greninger Source Type: research
Clinical characteristics and outcomes of acute liver failure in neonates: a retrospective cohort in China
Conclusion: Hypoxic/ischemic injury and infection are the predominant etiologies of NALF in China. The overall prognosis of NALF is poor, but its short-term prognosis is determined by the etiology. What is Known: • Neonatal acute liver failure (NALF) is a rare disorder with limited cohort studies, especially in China. • Gestational alloimmune liver disease, viral infections (especially herpes simplex virus), metabolic diseases and ischemic insults are common etiologies of NALF, which are significantly different from other populations. • There are no reliable biochemical markers to predict the outcome of NALF. What is...
Source: Herpes - April 30, 2024 Category: Infectious Diseases Authors: Suhua Xu Peng Zhang Mengmeng Ge Yuanyuan Shan Guoqiang Cheng Source Type: research
Effect of dolutegravir on ferritin, iron, and C-reactive protein among people living with HIV and co-infections
Conclusion: The presence of co-infections in PLWH is associated with higher VL and with chronic inflammation. Ferritin and CRP decreased on dolutegravir-based ART but remained higher in people with co-infections despite similar rates of virologic suppression. (Source: Southern African Journal of HIV Medicine)
Source: Southern African Journal of HIV Medicine - April 30, 2024 Category: African Health Authors: Bridget Kamurai Source Type: research
< em > In vitro < /em > evaluation of inhibitory effect of < em > Lactobacillus reuteri < /em > supernatant on the replication of herpes simplex virus type 1 and expression of < em > UL54, UL52 < /em > and < em > UL27 < /em > genes
CONCLUSION: The study findings indicated that the supernatant of L. reuteri has a potent anti-HSV-1 effect especially if it is incubated with the virus before inoculation into the cell. Its possible antiviral mechanism is to inhibit the virus by binding to it or changing the surface structure of the virus. Metabolites of L. reuteri can be considered as a novel inhibitor of HSV-1 infection.PMID:38682053 | PMC:PMC11055432 | DOI:10.18502/ijm.v16i1.14877 (Source: Iranian Journal of Microbiology)
Source: Iranian Journal of Microbiology - April 29, 2024 Category: Microbiology Authors: Faezeh Ebneali Mohammad Shayestehpour Ahmad Piroozmand Hossein Sedaghat Shaghayegh Yazdani Zahrasadat Fateminasab Source Type: research
Enhanced therapeutic efficacy for glioblastoma immunotherapy with an oncolytic herpes simplex virus armed with anti-PD-1 antibody and IL-12
In this study, we developed a new generation of oncolytic herpes simplex virus C5252 by deletion of a 15-kb internal repeat region and both copies of γ34.5 genes. Additionally, C5252 was armed with anti-programmed cell death protein 1 antibody and interleukin-12 to enhance its therapeutic efficacy for glioblastoma immune-virotherapy. In vitro and in vivo experiments demonstrate that C5252 has a remarkable safety profile and potent anti-tumor activity against glioblastoma. Mechanistic studies demonstrated that C5252 specifically induces cell apoptosis by caspase-3/7 activation via downregulating ciliary neurotrophic factor...
Source: Herpes - April 29, 2024 Category: Infectious Diseases Authors: Lei Wang Xusha Zhou Xiaoqing Chen Yuanyuan Liu Yue Huang Yuan Cheng Peigen Ren Jing Zhao Grace Guoying Zhou Source Type: research
In vitro evaluation of inhibitory effect of Lactobacillus reuteri supernatant on the replication of herpes simplex virus type 1 and expression of UL54, UL52 and UL27 genes
CONCLUSION: The study findings indicated that the supernatant of L. reuteri has a potent anti-HSV-1 effect especially if it is incubated with the virus before inoculation into the cell. Its possible antiviral mechanism is to inhibit the virus by binding to it or changing the surface structure of the virus. Metabolites of L. reuteri can be considered as a novel inhibitor of HSV-1 infection.PMID:38682053 | PMC:PMC11055432 | DOI:10.18502/ijm.v16i1.14877 (Source: Herpes)
Source: Herpes - April 29, 2024 Category: Infectious Diseases Authors: Faezeh Ebneali Mohammad Shayestehpour Ahmad Piroozmand Hossein Sedaghat Shaghayegh Yazdani Zahrasadat Fateminasab Source Type: research
